Earlier this year, Daiichi Sankyo Global Head of Oncology Ken Keller told pharmaphorum about the company’s big year, with ...

In a second M&A announcement today, Zymeworks has reached an agreement to buy Theravance Biopharma, claiming rights to ...

French pharma company Ipsen has agreed to buy cancer biotech Kartos Therapeutics of the US for $450 million upfront, gaining ...

Viridian Therapeutics has fired a shot across Amgen's bows with FDA approval of Lumvoa, the first direct rival to Amgen's ...

The UK government has teamed up with Eli Lilly on a range of initiatives, backed with £85 million in funding, to expand ...

Pressure is building on Amgen to withdraw rare disease therapy Tavneos, after the EMA's human medicine committee followed the FDA in recommending that its benefits no longer outweigh its risks. At its ...

In a landmark decision for people with early type 1 diabetes (T1D) in the UK, Sanofi's first-of-its-kind therapy Tzield, ...

At its latest R&D update, Moderna revealed a move into the pioneering in vivo CAR-T category, adding another treatment class ...

Designing and implementing global patient support programmes (PSPs) is becoming increasingly complex. While many programmes ...

Two years after its first approval for an ultra-rare lipid disorder, Ionis' Tryngolza has been approved by the FDA for severe ...

Around a third of adults in England are now living with obesity, and new cases are rising most quickly in younger adults, ...

The industry tends to treat manufacturing as a back-end operational concern. For advanced therapies, it isn't. In cell and ...